Combination of KIT gene silencing and tocopherol succinate may offer improved therapeutic approaches for human mastocytosis

British Journal of Haematology

Volumn 148, Issue 1, 2010, Pages 59-68

  Ruano, Irene ^a   Gargini, Ricardo ^a   Izquierdo, Marta ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Cancer; Cell toxicity; Gene therapy; Mastocytosis

Indexed keywords

ALPHA TOCOPHEROL; ALPHA TOCOPHEROL SUCCINATE; IMATINIB; STEM CELL FACTOR; TOCOFERSOLAN;

ALLELE; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL LINE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MASTOCYTOSIS; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOTRANSPLANTATION;

ALPHA-TOCOPHEROL; ANIMALS; APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; COMBINED MODALITY THERAPY; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; GENE THERAPY; HUMANS; MASTOCYTOSIS; MICE; MICE, NUDE; MUTATION; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-KIT; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 72249084733     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07918.x     Document Type: Article

References (47)

1. Akin, C., Brockow, K., D'Ambrosio, C., Kirshenbaum, A.S., Ma, Y., Longley, B.J. Metcalfe, D.D. (2003) Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated KIT. Experimental Hematology, 31, 686 692.
2. Ashman, L.K., Ferrao, P., Cole, S.R. Cambareri, A.C. (1999) Effects of mutant c-Kit in early myeloid cells. Leukaemia & Lymphoma, 34, 451 461.
3. Brummelkamp, T.R., Bernards, R. Agami, R. (2002) Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell, 2, 243 247.
4. Butterfield, J.H., Weiler, D., Dewald, G. Gleich, G.J. (1988) Establishment of an immature mast cell line from a patient with mast cell leukemia. Leukemia Research, 12, 345 355.
5. Capdeville, R., Buchdunger, E., Zimmermann, J. Matter, A. (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nature Reviews. Drug discovery, 1, 493 502.
6. Clarke, A.R., Purdie, C.A., Harrison, D.J., Morris, R.G., Bird, C.C., Hooper, M.L. Wyllie, A.H. (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature, 362, 849 852.
7. Dalen, H. Neuzil, J. (2003) Alpha-tocopheryl succinate sensitises a T lymphoma cell line to TRAIL-induced apoptosis by suppressing NF-kappaB activation. British Journal of Cancer, 88, 153 158.
8. Duursma, A.M. Agami, R. (2003) Ras interference as cancer therapy. Seminars in Cancer Biology, 13, 267 273.
9. Escribano, L., Akin, C., Castells, M., Orfao, A. Metcalfe, D.D. (2002) Mastocytosis: current concepts in diagnosis and treatment. Annals of Hematology, 81, 677 690.
10. Garcia-Montero, A.C., Jara-Acevedo, M., Teodosio, C., Sanchez, M.L., Nunez, R., Prados, A., Aldanondo, I., Sanchez, L., Dominguez, M., Botana, L.M., Sanchez-Jimenez, F., Sotlar, K., Almeida, J., Escribano, L. Orfao, A. (2006) KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood, 108, 2366 2372.
11. Haller, F., Detken, S., Schulten, H.J., Happel, N., Gunawan, B., Kuhlgatz, J. Fuzesi, L. (2007) Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Annals of Surgical Oncology, 14, 526 532.
12. Hartmann, K., Wardelmann, E., Ma, Y., Merkelbach-Bruse, S., Preussner, L.M., Woolery, C., Baldus, S.E., Heinicke, T., Thiele, J., Buettner, R. Longley, B.J. (2005) Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology, 129, 1042 1046.
13. Hines, S.J., Organ, C., Kornstein, M.J. Krystal, G.W. (1995) Coexpression of the c-kit and stem cell factor genes in breast carcinomas. Cell Growth and Differentiation, 6, 769 779.
14. Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., Muhammad Tunio, G., Matsuzawa, Y., Kanakura, Y., Shinomura, Y. Kitamura, Y. (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 279, 577 580. (Pubitemid 28067289)
15. Inoue, M., Kyo, S., Fujito, M., Enomoto, T. Kondoh, G. (1994) Coexpression of c-kit receptor and the stem cell factor receptor in gynecological tumors. Cancer Research, 54, 3049 3053.
16. Jaattela, M., Wissing, D., Kokholm, K., Kallunki, T. Egeblad, M. (1998) Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteases. EMBO Journal, 17, 6124 6134.
17. Johnson, F.M., Krug, L.M., Tran, H.T., Shoaf, S., Prieto, V.G., Tamboli, P., Peeples, B., Patel, J. Glisson, B.S. (2006) Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma. Cancer, 106, 366 374.
18. Kempna, P., Reiter, E., Arock, M., Azzi, A. Zingg, J.M. (2004) Inhibition of HMC-1 mast cell proliferation by vitamin E: involvement of the protein kinase B pathway. Journal of Biological Chemistry, 279, 50700 50709.
19. Kim, D.H. Rossi, J.J. (2007) Strategies for silencing human disease using RNA interference. Nature Reviews. Genetics, 8, 173 184.
20. Krystal, G.W., Hines, S.J. Organ, C.P. (1996) Autocrine growth of small cell lung cancer mediated by co-expression of c-kit ans stem cell factor. Cancer Research, 56, 370 376.
21. Lim, S.J., Lee, Y.J., Park, D.H., Lee, E., Choi, M.K., Park, W., Chun, K.H., Choi, H.G. Cho, J.S. (2007) Alpha-tocopheryl succinate sensitizes human colon cancer cells to exisulind-induced apoptosis. Apoptosis, 12, 423 431.
22. Longley, B.J., Reguera, M.J. Ma, Y. (2001) Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leukemia Research, 25, 571 576.
23. Ma, Y., Longley, B.J., Wang, X., Blount, J.L., Langley, K. Caughey, G.H. (1999) Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms. Journal of Investigative Dermatology, 112, 165 170.
24. Martinez, L.A., Naguibneva, I., Lehrmann, H., Vervisch, A., Tchenio, T., Lozano, G. Harel-Bellan, A. (2002) Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proceedings of the National Academy of Sciences of the United States of America, 99, 14849 14854.
25. McLean, S.R., Gana-Weisz, M., Hartzoulakis, B., Frow, R., Whelan, J., Selwood, D. Boshoff, C. (2005) Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala. Molecular Cancer Therapeutics, 4, 2008 2015.
26. Mol, C.D., Dougan, D.R., Schneider, T.R., Skene, R.J., Kraus, M.L., Scheibe, D.N., Snell, G.P., Zou, H., Sang, B.C. Wilson, K.P. (2004) Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. Journal of Biological Chemistry, 279, 31655 31663.
27. Neuzil, J., Kagedal, K., Andera, L., Weber, C. Brunk, U.T. (2002) Vitamin E analogs: a new class of multiple action agents with anti-neoplastic and anti-atherogenic activity. Apoptosis, 7, 179 187.
28. Neuzil, J., Tomasetti, M., Zhao, Y., Dong, L.F., Birringer, M., Wang, X.F., Low, P., Wu, K., Salvatore, B.A. Ralph, S.J. (2007) Vitamin E analogs, a novel group of "mitocans," as anticancer agents: the importance of being redox-silent. Molecular Pharmacology, 71, 1185 1199.
29. Olivieri, A. Manzione, L. (2007) Dasatinib: a new step in molecular target therapy. Annals of Oncology, 18 (Suppl. 6 vi42 vi46.
30. Orfao, A., Garcia-Montero, A.C., Sanchez, L. Escribano, L. (2007) Recent advances in the understanding of mastocytosis: the role of KIT mutations. British Journal of Haematology, 138, 12 30.
31. Perez-Soler, R. (2007) Erlotinib: recent clinical results and ongoing studies in non small cell lung cancer. Clinical Cancer Research, 13, s4589 s4592.
32. Prasad, K.N., Hernandez, C., Edwards-Prasad, J., Nelson, J., Borus, T. Robinson, W.A. (1994) Modification of the effect of tamoxifen, cis-platin, DTIC, and interferon-alpha 2b on human melanoma cells in culture by a mixture of vitamins. Nutrition and Cancer, 22, 233 245.
33. Quintas-Cardama, A., Aribi, A., Cortes, J., Giles, F.J., Kantarjian, H. Verstovsek, S. (2006) Novel approaches in the treatment of systemic mastocytosis. Cancer, 107, 1429 1439.
34. Raoul, C., Abbas-Terki, T., Bensadoun, J.C., Guillot, S., Haase, G., Szulc, J., Henderson, C.E. Aebischer, P. (2005) Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nature Medicine, 11, 423 428.
35. Rosato, R.R., Almenara, J.A. Grant, S. (2003) The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Research, 63, 3637 3645.
36. Roucou, X., Montessuit, S., Antonsson, B. Martinou, J.C. (2002) Bax oligomerization in mitochondrial membranes requires tBid (caspase-8-cleaved Bid) and a mitochondrial protein. Biochemical Journal, 368, 915 921.
37. Ruano, I. Izquierdo, M. (2009) Selective RNAi-mediated inhibition of mutated c-kit. Journal of RNAi and Gene Silencing, 5, 339 344.
38. Simbulan-Rosenthal, C.M., Rosenthal, D.S., Iyer, S., Boulares, H. Smulson, M.E. (1999) Involvement of PARP and poly(ADP-ribosyl)ation in the early stages of apoptosis and DNA replication. Molecular and Cellular Biochemistry, 193, 137 148.
39. Tomasetti, M., Rippo, M.R., Alleva, R., Moretti, S., Andera, L., Neuzil, J. Procopio, A. (2004) Alpha-tocopheryl succinate and TRAIL selectively synergise in induction of apoptosis in human malignant mesothelioma cells. British Journal of Cancer, 90, 1644 1653.
40. Tomasetti, M., Andera, L., Alleva, R., Borghi, B., Neuzil, J. Procopio, A. (2006) Alpha-tocopheryl succinate induces DR4 and DR5 expression by a p53-dependent route: implication for sensitisation of resistant cancer cells to TRAIL apoptosis. FEBS Letters, 580, 1925 1931.
41. Uriarte, S.M., Joshi-Barve, S., Song, Z., Sahoo, R., Gobejishvili, L., Jala, V.R., Haribabu, B., McClain, C. Barve, S. (2005) Akt inhibition upregulates FasL, downregulates c-FLIPs and induces caspase-8-dependent cell death in Jurkat T lymphocytes. Cell Death and Differentiation, 12, 233 242.
42. Valent, P., Akin, C., Sperr, W.R., Mayerhofer, M., Födinger, M., Fritsche-Polanz, R., Sotlar, K., Escribano, L., Arock, M., Horny, H.P. Metcalfe, D.D. (2005) Mastocytosis: pathology, genetics, and current options for therapy. Leukaemia & Lymphoma, 46, 35 48.
43. Vitali, R., Cesi, V., Nicotra, M.R., Donfrancesco, A., McDowell, H.P., Mannarino, O., Natali, P.G., Raschella, G. Dominici, C. (2003) c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited by STI-571. International Journal of Cancer, 106, 147 152.
44. Weber, T., Lu, M., Andera, L., Lahm, H., Gellert, N., Fariss, M.W., Korinek, V., Sattler, W., Ucker, D.S., Terman, A., Schroder, A., Erl, W., Brunk, U.T., Coffey, R.J., Weber, C. Neuzil, J. (2002) Vitamin E succinate is a potent novel antineoplastic agent with high selectivity and cooperativity with tumor necrosis factor-related apoptosis-inducing ligand (Apo2 ligand) in vivo. Clinical Cancer Research, 8, 863 869.
45. Xu, Z.W., Friess, H., Buchler, M.W. Solioz, M. (2002) Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents. Cancer Chemotherapy and Pharmacology, 49, 504 510.
46. Yu, W., Israel, K., Liao, Q.Y., Aldaz, C.M., Sanders, B.G. Kline, K. (1999) Vitamin E succinate (VES) induces Fas sensitivity in human breast cancer cells: role for Mr 43,000 Fas in VES-triggered apoptosis. Cancer Research, 59, 953 961.
47. Zermati, Y., De Sepulveda, P., Feger, F., Letard, S., Kersual, J., Casteran, N., Gorochov, G., Dy, M., Ribadeau Dumas, A., Dorgham, K., Parizot, C., Bieche, Y., Vidaud, M., Lortholary, O., Arock, M., Hermine, O. Dubreuil, P. (2003) Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene, 22, 660 664.